Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation

Circulation: Arrhythmia and Electrophysiology

Volumn 6, Issue 4, 2013, Pages 697-704

  Ling, Liang Han ^a,b   Kalman, Jonathan M ^b   Ellims, Andris H ^a   Iles, Leah M ^a   Medi, Caroline ^a,b   Sherratt, Craig ^a   Kaye, David M ^a,b   Hare, James L ^a   Kistler, Peter M ^a   Taylor, Andrew J ^a  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Ablation; Cardiomyopathies; MRI; T1 mapping; Tachycardia

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE;

ADULT; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CATHETER ABLATION; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FIBROSIS; HEART EJECTION FRACTION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FIBROSIS; HUMAN; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA MEDIATED CARDIOMYOPATHY; TREATMENT OUTCOME;

ABLATION; CARDIOMYOPATHIES; MRI; T1 MAPPING; TACHYCARDIA;

ADULT; AGED; CARDIOMYOPATHIES; CATHETER ABLATION; CONTRAST MEDIA; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; FIBROSIS; GADOLINIUM DTPA; HEART VENTRICLES; HUMANS; LINEAR MODELS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; TACHYCARDIA, SUPRAVENTRICULAR; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING; VICTORIA;

EID: 84884529777     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.113.000681     Document Type: Article

References (45)

1. Medi C, Kalman JM, Haqqani H, Vohra JK, Morton JB, Sparks PB, Kistler PM. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol. 2009;53: 1791-1797.
2. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol. 1986;57: 563-570.
3. Hendrick DA, Smith AC, Kratz JM, Crawford FA, Spinale FG. The pig as a model of tachycardia and dilated cardiomyopathy. Lab Anim Sci. 1990;40: 495-501.
4. Moe GW, Stopps TP, Howard RJ, Armstrong PW. Early recovery from heart failure: insights into the pathogenesis of experimental chronic pacing- induced heart failure. J Lab Clin Med. 1988;112: 426-432.
5. Redfield MM, Aarhus LL, Wright RS, Burnett JC Jr. Cardiorenal and neurohumoral function in a canine model of early left ventricular dysfunction. Circulation. 1993;87: 2016-2022.
6. Dandamudi G, Rampurwala AY, Mahenthiran J, Miller JM, Das MK. Persistent left ventricular dilatation in tachycardia-induced cardiomyopathy patients after appropriate treatment and normalization of ejection fraction. Heart Rhythm. 2008;5: 1111-1114.
7. Chin A, Badri M, Ntusi NB, Okreglicki A. The clinical, electrocardiographic and echocardiographic characteristics and long-term outcome of patients with tachycardia-induced cardiomyopathy. Cardiovasc J Afr. 2012;23: 136-142.
8. Watanabe H, Okamura K, Chinushi M, Furushima H, Tanabe Y, Kodama M, Aizawa Y. Clinical characteristics, treatment, and outcome of tachycardia induced cardiomyopathy. Int Heart J. 2008;49: 39-47.
9. Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation. 2004;110: 247-252.
10. Spinale FG, Holzgrefe HH, Mukherjee R, Arthur SR, Child MJ, Powell JR, Koster WH. LV and myocyte structure and function after early recovery from tachycardia-induced cardiomyopathy. Am J Physiol. 1995;268(2 Pt 2):H836-H847.
11. Spinale FG, Tomita M, Zellner JL, Cook JC, Crawford FA, Zile MR. Collagen remodeling and changes in LV function during development and recovery from supraventricular tachycardia. Am J Physiol. 1991;261(2 Pt 2):H308-H318.
12. Spinale FG, Zellner JL, Johnson WS, Eble DM, Munyer PD. Cellular and extracellular remodeling with the development and recovery from tachycardia-induced cardiomyopathy: changes in fibrillar collagen, myocyte adhesion capacity and proteoglycans. J Mol Cell Cardiol. 1996;28: 1591-1608.
13. Spinale FG, Zellner JL, Tomita M, Crawford FA, Zile MR. Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy. Circ Res. 1991;69: 1058-1067.
14. Saoudi N, Cosio F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a statement from a joint expert group from the working group of arrhythmias of the European Society of Cardiology and the North American Society of pacing and electrophysiology. Eur Heart J. 2001;22: 1162-1182.
15. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30: 473-483.
16. Taylor AJ, Al-Saadi N, Abdel-Aty H, Schulz-Menger J, Messroghli DR, Friedrich MG. Detection of acutely impaired microvascular reperfusion after infarct angioplasty with magnetic resonance imaging. Circulation. 2004;109: 2080-2085.
17. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52: 1574-1580.
18. Saranathan M, Rochitte CE, Foo TK. Fast, three-dimensional free-breathing MR imaging of myocardial infarction: a feasibility study. Magn Reson Med. 2004;51: 1055-1060.
19. Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley CT, Bluemke DA. T1 mapping of the myocardium: intra-individual assessment of the effect of field strength, cardiac cycle and variation by myocardial region. J Cardiovasc Magn Reson. 2012;14:27.
20. Gai N, Turkbey EB, Nazarian S, van der Geest RJ, Liu CY, Lima JA, Bluemke DA. T1 mapping of the gadolinium-enhanced myocardium: adjustment for factors affecting interpatient comparison. Magn Reson Med. 2011;65: 1407-1415.
21. Hsu LF, Jaïs P, Sanders P, Garrigue S, Hocini M, Sacher F, Takahashi Y, Rotter M, Pasquié JL, Scavée C, Bordachar P, Clémenty J, Haïssaguerre M. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med. 2004;351: 2373-2383.
22. Van Gelder IC, Crijns HJ, Blanksma PK, Landsman ML, Posma JL, Van Den Berg MP, Meijler FL, Lie KI. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol. 1993;72: 560-566.
23. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 1997;30: 1039-1045.
24. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol. 1997;29: 709-715.
25. Shannon RP, Komamura K, Stambler BS, Bigaud M, Manders WT, Vatner SF. Alterations in myocardial contractility in conscious dogs with dilated cardiomyopathy. Am J Physiol. 1991;260(6 Pt 2):H1903-H1911.
26. Howard RJ, Stopps TP, Moe GW, Gotlieb A, Armstrong PW. Recovery from heart failure: structural and functional analysis in a canine model. Can J Physiol Pharmacol. 1988;66: 1505-1512.
27. Weber KT, Pick R, Silver MA, et al. Fibrillar collagen and remodeling of dilated canine left ventricle. Circulation. 1990;82: 1387-1401.
28. Flack EC, Lindsey ML, Squires CE, Kaplan BS, Stroud RE, Clark LL, Escobar PG, Yarbrough WM, Spinale FG. Alterations in cultured myocardial fibroblast function following the development of left ventricular failure. J Mol Cell Cardiol. 2006;40: 474-483.
29. Burstein B, Libby E, Calderone A, Nattel S. Differential behaviors of atrial versus ventricular fibroblasts: a potential role for platelet-derived growth factor in atrial-ventricular remodeling differences. Circulation. 2008;117: 1630-1641.
30. Karagueuzian HS. Targeting cardiac fibrosis: a new frontier in antiarrhythmic therapy? Am J Cardiovasc Dis. 2011;1: 101-109.
31. John BT, Tamarappoo BK, Titus JL, Edwards WD, Shen WK, Chugh SS. Global remodeling of the ventricular interstitium in idiopathic myocardial fibrosis and sudden cardiac death. Heart Rhythm. 2004;1: 141-149.
32. Hookana E, Junttila MJ, Puurunen VP, Tikkanen JT, Kaikkonen KS, Kortelainen ML, Myerburg RJ, Huikuri HV. Causes of nonischemic sudden cardiac death in the current era. Heart Rhythm. 2011;8: 1570-1575.
33. Chugh SS, Chung K, Zheng ZJ, John B, Titus JL. Cardiac pathologic findings reveal a high rate of sudden cardiac death of undetermined etiology in younger women. Am Heart J. 2003;146: 635-639.
34. Stein M, Noorman M, van Veen TA, Herold E, Engelen MA, Boulaksil M, Antoons G, Jansen JA, van Oosterhout MF, Hauer RN, de Bakker JM, van Rijen HV. Dominant arrhythmia vulnerability of the right ventricle in senescent mice. Heart Rhythm. 2008;5: 438-448.
35. Massare J, Berry JM, Luo X, Rob F, Johnstone JL, Shelton JM, Bassel- Duby R, Hill JA, Naseem RH. Diminished cardiac fibrosis in heart failure is associated with altered ventricular arrhythmia phenotype. J Cardiovasc Electrophysiol. 2010;21: 1031-1037.
36. Ten Tusscher KH, Panfilov AV. Influence of diffuse fibrosis on wave propagation in human ventricular tissue. Europace. 2007;(9 suppl 6):vi38-vi45.
37. de Bakker JM, van Rijen HM. Continuous and discontinuous propagation in heart muscle. J Cardiovasc Electrophysiol. 2006;17: 567-573.
38. Kawara T, Derksen R, de Groot JR, Coronel R, Tasseron S, Linnenbank AC, Hauer RN, Kirkels H, Janse MJ, de Bakker JM. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation. 2001;104: 3069-3075.
39. Miragoli M, Salvarani N, Rohr S. Myofibroblasts induce ectopic activity in cardiac tissue. Circ Res. 2007;101: 755-758.
40. Morita N, Lee JH, Xie Y, Sovari A, Qu Z, Weiss JN, Karagueuzian HS. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J Am Coll Cardiol. 2011;57: 366-375.
41. Morita N, Sovari AA, Xie Y, et al. Increased susceptibility of aged hearts to ventricular fibrillation during oxidative stress. Am J Physiol Heart Circ Physiol. 2009;297:H1594-1605.
42. Xie LH, Chen F, Karagueuzian HS, Weiss JN. Oxidative-stress-induced afterdepolarizations and calmodulin kinase II signaling. Circ Res. 2009;104: 79-86.
43. Nakamura R, Egashira K, Machida Y, Hayashidani S, Takeya M, Utsumi H, Tsutsui H, Takeshita A. Probucol attenuates left ventricular dysfunction and remodeling in tachycardia-induced heart failure: roles of oxidative stress and inflammation. Circulation. 2002;106: 362-367.
44. Shite J, Qin F, Mao W, Kawai H, Stevens SY, Liang C. Antioxidant vitamins attenuate oxidative stress and cardiac dysfunction in tachycardiainduced cardiomyopathy. J Am Coll Cardiol. 2001;38: 1734-1740.
45. Sibley CT, Noureldin RA, Gai N, Nacif MS, Liu S, Turkbey EB, Mudd JO, van der Geest RJ, Lima JA, Halushka MK, Bluemke DA. T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology. 2012;265: 724-732.